IGF1 and risk of additional breast cancer in the WHEL study

Endocrine-Related Cancer

Volumn 18, Issue 2, 2011, Pages 235-244

  Al Delaimy, Wael K ^a,b   Flatt, Shirley W ^a   Natarajan, Loki ^a   Laughlin, Gail A ^b   Rock, Cheryl L ^a   Gold, Ellen B ^c   Caan, Bette J ^d   Parker, Barbara A ^a   Pierce, John P ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CYSTEINE RICH PROTEIN 61; INSULIN; LEPTIN; SOMATOMEDIN C; TAMOXIFEN;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVOR; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PROTEIN BINDING;

ADULT; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS;

EID: 79953172901     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0121     Document Type: Article

References (55)

1. Al-Delaimy WK, Natarajan L, Rock CL, Sun S, Flatt SW & Pierce JP 2006 Insulin-like growth factor I, insulin-like growth factor I binding protein 1, insulin, glucose, and leptin serum levels are not influenced by a reduced-fat, high-fiber diet intervention. Cancer Epidemiology, Biomarkers and Prevention 15 1238-1239. (doi:10.1158/1055-9965.EPI-06-0160)
2. American Cancer Society 2005 In Breast Cancer Facts and Figures 2005-2006. Atlanta, GA, USA: American Cancer Society, Inc.
3. American Joint Committee on Cancer 2002 In Cancer Staging Manual. Eds FL Green, DL Page, ID Fleming, AG Fritz, CM Balch, DG Haller & M Morrow. 6th Edn. New York, NY, USA: Springer-Verlag.
4. Bernstein J, Langholz B, Haile R, Bernstein L, Thomas D, Stovall M, Malone K, Lynch C, Olsen J, Anton-Culver H et al. 2004 Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. Breast Cancer Research 6 R199-R214. (doi:10.1186/bcr771)
5. Bruning P, Bonfrer J, van Noord P, Hart A, de Jong-Bakker M & Nooijen W 1992 Insulin resistance and breast-cancer risk. International Journal of Cancer 52 511-516. (doi:10.1002/ijc.2910520402)
6. Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Galimberti V, Cassano E et al. 2009 Randomized double-blind 2X2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. Journal of Clinical Oncology 27 3749-3756. (doi:10.1200/JCO.2008.19.3797)
7. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351 1451-1466.
8. Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK & Roddam AW 2010 Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncology 11 530-542. (doi:10.1016/S1470-2045(10)70095-4)
9. Erickson K, Patterson RE, Flatt SW, Natarajan L, Parker BA, Heath DD, Laughlin GA, Saquib N, Rock CL & Pierce JP 2010 Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. Journal of Clinical Oncology 29 54-60. (doi:10.1200/JCO.2010.29.3183)
10. Figueroa JA, Jackson JG, McGuire WL, Krywicki RF & Yee D 1993 Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. Journal of Cellular Biochemistry 52 196-205. (doi:10.1002/jcb.240520211)
11. Fischer S, Hanefeld M, Haffner SM, Fusch C, Schwanebeck U, Kohler C, Fucker K & Julius U 2002 Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetologica 39 105-110. (doi:10.1007/s005920200027)
12. Goldstein L & Langholz B 1992 Asymptotic theory for nested case-control sampling in the Cox regression model. Annals of Statistics 20 1903-1928. (doi:10.1214/aos/1176348895)
13. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B & Hood N 2002 Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. Journal of Clinical Oncology 20 42-51. (doi:10.1200/JCO.20.1.42)
14. Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J & Hood N 2005 Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? Journal of Clinical Oncology 23 6037-6042. (doi:10.1200/JCO.2005. 02.048)
15. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL et al. 2009 Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute 101 48-60.
16. Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R & Rosen JM 2000 Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene 19 889-898. (doi:10.1038/sj.onc.1203386)
17. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE & Pollak M 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 1393-1396. (doi:10.1016/S0140-6736(97)10384-1)
18. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K et al. 2000 Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arteriosclerosis, Thrombosis, and Vascular Biology 20 1595-1599. (Pubitemid 30353893)
19. Johnson-Kozlow M, Rock CL, Gilpin EA, Hollenbach KA & Pierce JP 2007 Validation of the WHI brief physical activity questionnaire among women diagnosed with breast cancer. American Journal of Health Behavior 31 193-202.
20. Kaaks R, Lundin E, Rinaldi S, Manjer J, Biessy C, Soderberg S, Lenner P, Janzon L, Riboli E, Berglund G et al. 2002 Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes and Control 13 307-316. (doi:10.1023/A:1015270324325)
21. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, Van Gils CH, Van Noord PA, Rinaldi S, Riboli E, Seidell JC, Grobbee DE & Peeters PH 2003 Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer. International Journal of Cancer 106 90-95. (doi:10.1002/ijc.11193)
22. Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N et al. 2007 Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. Journal of Clinical Endocrinology and Metabolism 92 1041-1048. (doi:10.1210/jc.2006-1858)
23. Krajcik RA, Borofsky ND, Massardo S & Orentreich N 2002 Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiology, Biomarkers and Prevention 11 1566-1573. (Pubitemid 36020008)
24. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H et al. 2002 Disruption of adiponectin causes insulin resistance and neointimal formation. Journal of Biological Chemistry 277 25863-25866. (doi:10.1074/jbc.C200251200)
25. Langholz B & Thomas DC 1990 Nested case-control and case-cohort methods of sampling from a cohort: a critical comparison. American Journal of Epidemiology 131 169-176. (Pubitemid 20014710)
26. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR & Hux JE 2008 The impact of diabetes on survival following breast cancer. Breast Cancer Research and Treatment 109 389-395. (doi:10.1007/s10549-007-9654-0)
27. Lubin JH & Gail MH 1984 Biased selection of controls for case-control analyses of cohort studies. Biometrics 40 63-75. (doi:10.2307/2530744)
28. Macaulay VM 1992 Insulin-like growth factors and cancer. British Journal of Cancer 65 311-320. (doi:10.1038/bjc.1992.65)
29. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G et al. 2004 Adiponectin and breast cancer risk. Journal of Clinical Endocrinology and Metabolism 89 1102-1107. (doi:10.1210/jc.2003-031804)
30. Matsubara M, Maruoka S & Katayose S 2002 Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. European Journal of Endocrinology 147 173-180. (doi:10.1530/eje.0.1470173)
31. Mayer D, Shukla A & Enzmann H 2008 Proliferative effects of insulin analogues on mammary epithelial cells. Archives of Physiology and Biochemistry 114 38-44. (doi:10.1080/13813450801900645)
32. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R, Goldfine ID & Belfiore A 1992 Insulin receptor expression and function in human breast cancer cell lines. Cancer Research 52 3924-3930.
33. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y & Noguchi S 2003 Association of serum adiponectin levels with breast cancer risk. Clinical Cancer Research 9 5699-5704. (Pubitemid 37499493)
34. Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schunemann HJ, Ram M, Freudenheim JL, Sieri S, Trevisan M et al. 2002 Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiology, Biomarkers and Prevention 11 1361-1368. (Pubitemid 35340370)
35. Newman VA, Thomson CA, Rock CL, Flatt SW, Kealey S, Bardwell WA, Caan BJ & Pierce JP 2005 Achieving substantial changes in eating behavior among women previously treated for breast cancer - an overview of the intervention. Journal of the American Dietetic Association 105 382-391. (doi:10.1016/j.jada. 2004.12.008)
36. Ng EH, Ji CY, Tan PH, Lin V, Soo KC & Lee KO 1998 Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients. Annals of Surgical Oncology 5 194-201. (doi:10.1007/BF02303854)
37. Oh Y 1998 IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Research and Treatment 47 283-293. (doi:10.1023/A:1005911319432)
38. Pasanisi P, Venturelli E, Morelli D, Fontana L, Secreto G & Berrino F 2008 Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiology, Biomarkers and Prevention 17 1719-1722. (doi:10.1158/1055-9965.EPI-07-0654)
39. Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N & Trichopoulos D 2000 Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes and Control 11 383-388. (doi:10.1023/A: 1008903727238)
40. Pierce JP, Faerber S, Wright FA, Rock CL, Newman V, Flatt SW, Kealey S, Jones VE, Caan BJ, Gold EB et al. 2002 A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study. Controlled Clinical Trials 23 728-756. (doi:10.1016/S0197-2456(02)00241-6)
41. Rajaram S, Baylink DJ & Mohan S 1997 Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocrine Reviews 18 801-831. (doi:10.1210/er.18.6.801)
42. Renehan A, Zwahlen M, Minder C, O'Dwyer S, Shalet S & Egger M 2004 Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 1346-1353. (doi:10.1016/S0140-6736(04)16044-3)
43. Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron- Ruault MC et al. 2006 IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocrine-Related Cancer 13 593-605. (doi:10.1677/erc.1.01150)
44. Sakauchi F, Nojima M, Mori M, Wakai K, Suzuki S, Tamakoshi A, Ito Y, Watanabe Y, Inaba Y, Tajima K et al. 2009 Serum insulin-like growth factors I and II, insulinlike growth factor binding protein-3 and risk of breast cancer in the Japan Collaborative Cohort study. Asian Pacific Journal of Cancer Prevention 10 (Suppl) 51-55.
45. Sauter ER, Garofalo C, Hewett J, Hewett JE, Morelli C & Surmacz E 2004 Leptin expression in breast nipple aspirate fluid (NAF) and serum is influenced by body mass index (BMI) but not by the presence of breast cancer. Hormone and Metabolic Research 36 336-340. (doi:10.1055/s-2004-814490)
46. Smith-Kirwin SM, O'Connor DM, De Johnston J, Lancey ED, Hassink SG & Funanage VL 1998 Leptin expression in human mammary epithelial cells and breast milk. Journal of Clinical Endocrinology and Metabolism 83 1810-1813. (doi:10.1210/jc.83.5.1810)
47. Stattin P, Soderberg S, Biessy C, Lenner P, Hallmans G, Kaaks R & Olsson T 2004 Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Research and Treatment 86 191-196. (doi:10.1023/B:BREA.0000036782.11945.d7)
48. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C et al. 2002 Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51 1884-1888. (doi:10.2337/diabetes.51. 6.1884)
49. Straus DS 1994 Nutritional regulation of hormones and growth factors that control mammalian growth. FASEB Journal 8 6-12. (Pubitemid 24047405)
50. Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles JM, Benedetto C & Mussa A 2000 Leptin expression in colorectal and breast cancer patients. International Journal of Molecular Medicine 5 421-426.
51. Thissen JP, Ketelslegers JM & Underwood LE 1994 Nutritional regulation of the insulin-like growth factors. Endocrine Reviews 15 80-101. (doi:10.1210/edrv-15-1-80)
52. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE & Zeleniuch-Jacquotte A 2000 Serum insulin-like growth factor-I and breast cancer. International Journal of Cancer 88 828-832. (doi:10.1002/1097-0215(20001201)88:5〈828::AID-IJC22〉3.0.CO;2-8)
53. Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS & Hankinson SE 2007 Plasma adiponectin concentrations and risk of incident breast cancer. Journal of Clinical Endocrinology and Metabolism 92 1510-1516. (doi:10.1210/jc.2006-1975)
54. Vadgama JV, Wu Y, Datta G, Khan H & Chillar R 1999 Plasma insulin-like growth factor-I and serum IGFbinding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57 330-340. (doi:10.1159/000012052)
55. Wauters M, Considine RV, Yudkin JS, Peiffer F, De Leeuw I & Van Gaal LF 2003 Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion. Hormone and Metabolic Research 35 92-96. (doi:10.1055/s-2003-39054)